Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statin-fibrate combination therapy.

A Shek1, M J Ferrill

  • 1Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211-0001, USA. ashek@uop.edu

The Annals of Pharmacotherapy
|August 4, 2001
PubMed
Summary

Combining statins and fibrates for severe mixed hyperlipidemia offers benefits, but carries a 0.12% risk of myopathy. Careful patient selection and counseling are crucial for safe and effective treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of bulimia nervosa with ondansetron.

The Annals of pharmacotherapy·2001
Same author

Consensus Statement on Alzheimer disease.

JAMA·1998
Same author

Fish oil therapy in IgA nephropathy.

The Annals of pharmacotherapy·1997
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Coadministration of statins and fibrates has been associated with severe myopathy and rhabdomyolysis.
  • Recent labeling changes have contraindicated combined use with fibric acid derivatives.
  • Clinicians require practical guidance for managing refractory mixed hyperlipidemia.

Purpose of the Study:

  • To offer recommendations for clinicians treating refractory mixed hyperlipidemia.
  • To evaluate the risks and benefits of combining statins and fibrates.

Main Methods:

  • A comprehensive literature search of MEDLINE and bibliographic databases was conducted.
  • Reviewed 36 clinical trials and 29 case reports on combination therapy with HMG-CoA reductase inhibitors and fibric acid derivatives.
  • Focused on the occurrence of rhabdomyolysis or myopathy.

Main Results:

  • Combination therapy with statins and fibrates increases muscle damage risk by 0.12%.
  • Risk factors for myopathy include advanced age, female gender, renal/liver disease, diabetes, hypothyroidism, and debilitation.
  • Niacin may be a safer alternative before considering fibrates.

Conclusions:

  • Statin-fibrate combination therapy provides significant benefits for severe mixed hyperlipidemia.
  • The 0.12% risk of myopathy is generally outweighed by lipid goal achievement benefits.
  • Cautious use, risk-benefit analysis, and patient counseling are essential for managing myopathy risks.

Related Experiment Videos